Additionally, an open question that remains unanswered for now is whether different GBM subtypes, such as proneural, mesenchymal, and classical GBM [44], respond differently to BMP4 treatment/CHRDL1-blockade. This evidence concerns the gene BMP4 and glioblastoma.